pixel

Investor Relations

Vivos Therapeutics, Inc. NASDAQ: VVOS

Vivos Therapeutics, Inc.
First Quarter 2022 Earnings Call

An Important Breakthrough in the Treatment for Mild-to-Moderate Obstructive Sleep Apnea

Vivos offers a multidisciplinary treatment protocol that uses nonsurgical, noninvasive, and cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and/or mild-to-moderate OSA. This revolutionary treatment is called The Vivos Method.
dentist demo

Latest Stock Information

Listen to Kirk Huntsman and Brad Amman at the

34th Annual Roth Conference

Investor Presentation

Download the Vivos Investor Presentation
Investor Relations Presentation Cover

Fast Company Selects Vivos Therapeutics for 2022

“World’s Most Innovative Companies” List

Corporate Leadership

Our leadership team is devoted to a singular mission: to rid the world of sleep apnea.

News

Patients Treated

Doctors Integrated + Trained

Over 1 Billion Potential Patients

Email Alerts

Stay informed and receive company updates straight to your inbox.

Investor Relations Contacts

Home Office

Vivos Therapeutics, Inc.
(866) 908-4867
7921 Southpark Plaza
Suite 210
Littleton, CO 
80120

Investor Relations

Julie Gannon
Investment Relations Officer
(720) 442-8113
7921 Southpark Plaza
Suite 210
Littleton, CO 
80120
Email:[email protected]

Phil Carlson / Scott Eckstein
KCSA Strategic Communications
(212) 896-1210
[email protected]

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: (212) 828-8436
Fax: (646) 536-3179
[email protected]